HomeCompareIBER vs ABBV

IBER vs ABBV: Dividend Comparison 2026

IBER yields 19.65% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IBER wins by $31.5K in total portfolio value
10 years
IBER
IBER
● Live price
19.65%
Share price
$10.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.5K
Annual income
$6,488.19
Full IBER calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — IBER vs ABBV

📍 IBER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIBERABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IBER + ABBV cover 4 of 12 monthsgood coverage

Jan
ABBV
Feb
Mar
Apr
ABBV
May
Jun
Jul
ABBV
Aug
Sep
Oct
ABBV
Nov
Dec
IBER pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IBER
Annual income on $10K today (after 15% tax)
$1,669.94/yr
After 10yr DRIP, annual income (after tax)
$5,514.96/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, IBER beats the other by $4,533.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IBER + ABBV for your $10,000?

IBER: 50%ABBV: 50%
100% ABBV50/50100% IBER
Portfolio after 10yr
$55.7K
Annual income
$3,821.32/yr
Blended yield
6.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IBER
No analyst data
Altman Z
17.6
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IBER buys
0
ABBV buys
0
No recent congressional trades found for IBER or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIBERABBV
Forward yield19.65%3.67%
Annual dividend / share$2.00$6.20
Payout ratio50%58%
1-year div growth0%4.7%
5-year div CAGR0%8.9%
Portfolio after 10y$71.5K$39.9K
Annual income after 10y$6,488.19$1,154.43
Total dividends collected$40.3K$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IBER vs ABBV ($10,000, DRIP)

YearIBER PortfolioIBER Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,665$1,964.64$11,520$399.75+$1.1KIBER
2$15,877$2,325.37$13,261$450.98+$2.6KIBER
3$19,712$2,724.40$15,255$508.41+$4.5KIBER
4$24,253$3,161.31$17,536$572.74+$6.7KIBER
5$29,586$3,635.14$20,145$644.78+$9.4KIBER
6$35,802$4,144.33$23,126$725.38+$12.7KIBER
7$42,995$4,686.87$26,532$815.52+$16.5KIBER
8$51,265$5,260.30$30,420$916.26+$20.8KIBER
9$60,715$5,861.78$34,855$1,028.80+$25.9KIBER
10$71,453$6,488.19$39,914$1,154.43+$31.5KIBER

IBER vs ABBV: Complete Analysis 2026

IBERStock

Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.

Full IBER Calculator →

ABBVHealthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this IBER vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IBER vs SCHDIBER vs JEPIIBER vs OIBER vs KOIBER vs MAINIBER vs JNJIBER vs MRKIBER vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.